Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 39: | Line 39: | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1954]] |
Revision as of 19:16, 30 July 2018
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute promyelocytic leukemia
- Chronic lymphocytic leukemia (CLL/SLL)
- CNS lymphoma
- Ewing's sarcoma
- Autologous HSCT conditioning regimens
- Allogeneic HSCT conditioning regimens
Patient drug information
- Busulfan (Myleran) patient drug information (Chemocare)[3]
- Busulfan (Myleran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval
Also known as
- Brand names: Busulfex, Myleran